Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Candel TherapeuticsCADL +7.38%30 14-Day RSI is 61.86 as of Jul. 18, 2026. GuruFocus rates CADL with a GF Score™ of 30/100. The stock has 3 warning signs investors should review. Among 1,424 Biotechnology companies, Candel Therapeutics ranks worse than 69.52% on this metric.
The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30.
The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.
Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.
RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections.
Candel Therapeutics 14-Day RSI Related Terms
CADL vs AURA, RIGL, NVCT: 14-Day RSI Comparison
For the Biotechnology subindustry, Candel Therapeutics's 14-Day RSI, along with its competitors' market caps and 14-Day RSI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Candel Therapeutics 14-Day RSI vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Candel Therapeutics's 14-Day RSI distribution charts can be found below:
* The bar in red indicates where Candel Therapeutics's 14-Day RSI falls into.
* Note that the formula uses a positive value for the average loss.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Candel Therapeutics (CADL) has a 14-Day RSI of 61.86 as of Jul. 18, 2026. Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. View historical data on Candel Therapeutics and its competitors. According to the industry distribution chart, Candel Therapeutics ranks #990 out of 1424 companies in the Biotechnology industry, placing it in the top 69.5%.
Is Candel Therapeutics' 14-Day RSI too high?
Candel Therapeutics' current 14-Day RSI is 61.86. The Biotechnology industry median 14-Day RSI is 47.29. Candel Therapeutics' value of 61.86 is 30.8% above this industry median. Based on the distribution chart, Candel Therapeutics ranks #990 out of 1424 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Candel Therapeutics has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Candel Therapeutics' 14-Day RSI compare to AURA and RIGL?
According to the Biotechnology industry distribution chart, Candel Therapeutics ranks #990 out of 1424 companies for 14-Day RSI. This places Candel Therapeutics in the lower half of its industry. The industry median 14-Day RSI is 47.29. Candel Therapeutics' value of 61.86 is 30.8% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 14-Day RSI for a Biotechnology company?
The median 14-Day RSI among Biotechnology companies is 47.29, based on 1,424 companies in the industry. Companies in the top quartile (top 25%) have a 14-Day RSI significantly above this median, while those in the bottom quartile fall well below. However, 14-Day RSI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Candel Therapeutics's current 14-Day RSI of 61.86 is 30.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 14-Day RSI mean?
A high 14-Day RSI can signal that a stock is expensive relative to its fundamentals. Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. View historical data on Candel Therapeutics and its competitors. For the Biotechnology industry, the median 14-Day RSI is 47.29 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Candel Therapeutics's current 14-Day RSI is 61.86. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Candel Therapeutics stock overvalued right now?
Candel Therapeutics (CADL) has a current 14-Day RSI of 61.86. The current 14-Day RSI is 61.86 and 30.8% above the Biotechnology industry median of 47.29. Candel Therapeutics' overall GF Score™ is 30/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 14-Day RSI calculated?
14-Day RSI is calculated from a company's financial statements. For Candel Therapeutics (CADL), the current 14-Day RSI is 61.86 as of Jul. 18, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Candel Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing off-the-shelf viral immunotherapies that elicit an individualized, systemic anti-tumor immune response to help patients fight cancer. The immune cells induced by these viral immunotherapies are believed to target patients' specific tumor antigens, potentially improving responses in immunologically hot tumors while at the same time infiltrating the tumor microenvironment, transforming non-inflamed cold tumors with limited immune response into hot tumors. The company has established two clinical off-the-shelf viral immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) constructs, respectively.
30GF Score
Get the complete analysis for CADL
14-Day RSI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CADL has been successfully added to your 
